Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Research type
Research Study
Full title
A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer.
IRAS ID
1011799
Contact name
Elena Bolanos Cascales
Contact email
Sponsor organisation
Janssen - Cilag International
ISRCTN Number
ISRCTN10699447
Research summary
Prostate cancer is a cancer that forms in the prostate, a male reproductive gland found below the bladder. Cancer is considered “advanced” if it spreads extensively to other parts of the body. Although treatments are available, they do not cure advanced prostate cancer. Over
time, disease gets worse and progresses to metastatic castration-resistant prostate cancer (mCRPC)*, showing the need for better treatment.
*prostate cancer that grows despite low levels of male hormones Pasritamig (JNJ-78278343) is a bispecific antibody** that targets a protein, human kallikrein 2, on tumor cells and cluster of differentiation 3 protein on T-cells (key cell in the immune system). This
activates T-cells, which aim at damaging tumor cells and stopping them from growing.
**type of protein that recognizes and attaches to 2 different targets JNJ-86974680 works by blocking a protein called adenosine A2A receptor present on cancer and immune cells. By blocking this protein, the drug helps immune cells (T cells) to stay active and attack the cancer cells more effectively. In this study, researchers want to identify the most suitable dose of Pasritamig and JNJ-86974680
and to find out how safe it is at the recommended dose.REC name
North West - Haydock Research Ethics Committee
REC reference
25/NW/0333
Date of REC Opinion
16 Dec 2025
REC opinion
Further Information Favourable Opinion